Accordingly, it becomes evident that the early reduction in elasticity values, rather than the baseline elasticity value, may carry more significance in predicting the treatment response for patients with breast cancer undergoing neoadjuvant chemotherapy, including those with HER2+ breast cancer receiving HER2-targeted therapy. The gene discussed is ERBB2; the disease is breast carcinoma.